Purpose: To investigate the serum heparanase concentration and heparanase activity of the patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Methods: This prospective study included 23 CRVO patients, 13 BRVO patients and 28 control subjects. Serum heparanase concentration was measured by ELISA. Serum heparanase activity was determined using a heparan degrading enzyme assay kit (Mountain View, CA, USA). Multivariate logistic regression was used to adjust for the possible confounding factors when comparing the difference in serum heparanase concentration and activity between patients with RVO and control subjects. Results: Patients with CRVO (3.963 AE 0.816 U/l) or BRVO (3.371 AE 1.522 U/l) had significantly higher levels of heparanase protein compared to controls (1.055 AE 0.902 U/l). This significance remained after adjusting for aforementioned confounding factors (CRVO versus control, p = 0.000, 95%CI: 2.450-4.488; BRVO versus control, p = 0.006, 95%CI: 0.776-4.050). Patients with CRVO (0.3587 AE 0.1498 U/ml) or BRVO (0.3616 AE 0.0570 U/ml) had significantly higher levels of heparanase activity compared to controls (0.1449 AE 0.0952 U/ml). The significance was maintained after adjusting for the aforementioned confounding factors (CRVO versus control, p = 0.012, 95%CI: 0.036-0.275; BRVO versus control, p = 0.000, 95%CI: 0.150-0.395). There was no significant difference in serum heparanase protein levels and activities between CRVO and BRVO groups before and after confounding factor adjustment. Conclusion: Our study provides the first direct clinical link between systemic heparanase protein levels and heparanase activity with RVO, suggesting a critical role for heparanase in the pathophysiology of RVO.
Introduction
Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic retinopathy (Cugati et al. 2006) . The 10-year cumulative incidence of RVO is approximately 1.6%, projecting to more than 150 000 new cases a year in the United States (Cugati et al. 2006) . It is estimated that approximately 16 million people worldwide have RVO in at least one eye (Rogers et al. 2010) . Depending on the extent of occlusion in retinal venous drainage, it is broadly classified as either central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Central retinal vein occlusion consists of retinal haemorrhages in all four quadrants of the fundus, while the haemorrhages seen in BRVO are largely localized to the area drained by the occlude branch retinal vein (Jonas et al. 2015) . Both types of RVO can be classified as ischaemic or non-ischaemic according to the areas of capillary non-perfusion (Bertelmann et al. 2016) .
The aetiology of RVO is still not completely understood, but is thought to involve a combination of three systemic changes known as Virchow's triad: (i) haemodynamic changes (venous stasis), (ii) degenerative changes of the vessel wall and (iii) blood hypercoagulability (Zhou et al. 2013) . These changes are associated with a number of vessel wall pathologies, including venous thrombosis and arteriosclerosis.
The molecular pathophysiology of vessel wall abnormalities leading to vascular events has recently implicated an enzyme called heparanase. Heparanase is a multifunctional molecule that has both enzymatic and nonenzymatic functions. Through its b-endoglucuronidase activity, heparanase cleaves the heparan sulphate side chains of heparan sulphate proteoglycans (HSPGs) into fragments of 10-20 sugar units (Vlodavsky et al. 1999) . Heparanase expression is limited in normal tissue, being restricted to keratinocytes, platelets and activated immune cells (Parish et al. 2001; Ilan et al. 2006) . In contrast, heparanase expression is dramatically upregulated in various disease states including cancer (Parish et al. 2001; Ilan et al. 2006) , inflammatory and autoimmune diseases (Lerner et al. 2011) , diabetes mellitus (Ziolkowski et al. 2012 ) and vessel wall pathologies (e.g. thrombosis and atherosclerosis) (Baker et al. 2012; Blich et al. 2013; Osterholm et al. 2013) .
Heparanase protein levels and activity have been shown to increase by threefold to 6.6-fold with progression of atherosclerotic lesions from stable to vulnerable plaques (Baker et al. 2009; Osterholm et al. 2013 ). This plaque progression towards vulnerability is associated with macrophage activation by heparanase, resulting in a marked induction of cytokine expression . Thus, heparanase overexpression is associated with mediating disease-induced changes in the thrombotic potential of blood vessels. As RVO is likely to follow a thrombotic event, we postulate a similar critical role for heparanase in the pathophysiology of both CRVO and BRVO.
Materials and Methods
This is a prospective observational case-control study approved by the Institutional Review Board of the First Affiliated Hospital of Kunming Medical University, and it is adherent to the Declaration of Helsinki. Informed consent was obtained from each patient before participating in the study. Thirty-six patients with RVO (23 with CRVO, 13 with BRVO) were included in the study. Inclusion criteria were RVO confirmed by stereoscopic biomicroscopy of the fundus and fluorescein angiography (FA) after ruling out other retinal pathologies. Classification of RVO as ischaemic or not was according to the FA findings (Bertelmann et al. 2016) . Exclusion criteria were the presence or history of cancer, systemic or intra-ocular inflammatory and autoimmune diseases, ocular trauma, intra-ocular surgery, laser treatment, renal dysfunction and atherosclerosis. Twenty-eight genderand age-matched patients with senile cataract or refractive error were included as the control group. Each patient underwent a complete ocular examination including BCVA with decimal charts, slit lamp examination, intraocular pressure (IOP) measurement, stereoscopic biomicroscopy of the fundus, axial length measured by A-ultrasonography, retinal thickness measurement using optical coherence tomography (OCT) and FA. Blood glucose, homocysteine, uric acid, total cholesterol, HDL cholesterol, LDL cholesterol, glycerine trilaurate, apolipoprotein A1, apolipoprotein B and lipoprotein (a) were measured with an autoanalyzer (Cobas 8000, Rotkreuz, Switzerland). Body mass index (BMI) was calculated as weight (kg)/height 2 (m 2 ). Diabetes and hypertension were classified according to the criteria of the American Diabetes Association (Mellitus 2003) , the European Society of Hypertension (Mancia et al. 2007) , respectively. Patients having history of diabetes, hypertension or glaucoma would be classified as having the respective disease.
Serum heparanase concentration was measured by ELISA using a commercially available kit with the detection range of 1.56-100 U/l (#KA1230, Abnova). Serum heparanase activity was determined using a heparan degrading enzyme assay kit with the detection range of 0.065-4.20 U/ml (#MK412, Takara Bio Inc.). Serum heparanase concentration and activity lower than the detection limit were considered as zero.
Multivariate logistic regression was used to adjust for the possible confounding factors including age, gender, axial length, diabetes mellitus, hypertension, glaucoma, homocysteine level, uric acid level and various atherosclerosis risk factors [i.e. HDL cholesterol, LDL cholesterol, total cholesterol, glycerine trilaurate, apolipoprotein A1, apolipoprotein B and lipoprotein (a), BMI] when comparing serum heparanase concentration and activity between patients with RVO and control subjects.
Results
Basic characteristics and clinical data of the study subjects are shown in Table 1 . There were 20 patients with ischaemic CRVO, three patients with non-ischaemic CRVO, 10 patients with ischaemic BRVO and three patients with non-ischaemic BRVO. Mean age of the 23 CRVO patients (13 males and 10 females), the 13 BRVO patients (seven males and six females) and the 28 control subjects (20 males and eight females) was 61.2 AE 13.4 years, 56.5 AE 13.9 years and 59.6 AE 13.5 years, respectively.
Patients with CRVO or BRVO have higher levels of heparanase protein compared to controls
As seen in Fig. 1 , we have found that patients with CRVO (3.963 AE 0.816 U/l) or BRVO (3.371 AE 1.522 U/l) have significantly higher levels of heparanase protein compared to controls (1.055 AE 0.902 U/l). This significance remained after adjusting for aforementioned confounding factors (CRVO versus control, p = 0.000, 95%CI: 2.450-4.488; BRVO versus control, p = 0.006, 95%CI: 0.776-4.050). There was no significant difference in heparanase protein levels between CRVO and BRVO groups before and after confounding factor adjustment.
Patients with CRVO or BRVO have higher heparanase activity compared to controls Figure 2 demonstrates that patients with CRVO (0.3587 AE 0.1498 U/ml) or BRVO (0.3616 AE 0.0570 U/ml) had significantly higher levels of heparanase activity compared to controls (0.1449 AE 0.0952 U/ml). The significance was maintained after adjusting for the aforementioned confounding factors (CRVO versus control, p = 0.012, 95%CI: 0.036-0.275; BRVO versus control, p = 0.000, 95%CI: 0.150-0.395). Again, there was no significant difference in heparanase activity between patients with CRVO and BRVO.
Discussion
Retinal vein occlusion continues to be a major cause of vision loss throughout the world, for which there is no definitive treatment. In addition to a variety of known risk factors (e.g. diabetes, atherosclerosis), our results suggest that heparanase is significantly involved in the pathophysiology of the disease. Our findings are in keeping with multiple other studies that have shown an association between heparanase and cardiovascular abnormalities such as atherosclerosis, which are in turn associated with RVO (Baker et al. 2009 (Baker et al. , 2012 Nadir et al. 2010; Blich et al. 2013; Osterholm et al. 2013 ). However, our study provides the first direct clinical link between systemic heparanase activity and heparanase protein levels with RVO.
Although the exact aetiology of RVO remains elusive, it is most likely to follow a thrombotic event (Karia 2010) . In CRVO, this may occur in the central retinal vein at the lamina cribrosa or at some point within the optic nerve posterior to the lamina cribrosa (Green et al. 1981; Jonas et al. 2015) . In BRVO, arterial compression of the vein at arteriovenous crossings is thought to incite thrombus formation by causing turbulent flow in combination with preexisting vascular endothelial damage secondary to systemic cardiovascular risk factors, such as atherosclerosis and diabetic microvascular disease (Karia 2010; Jonas et al. 2015) .
Heparanase most likely contributes to RVO by a variety of mechanisms. It is well recognized that inflammation affects the progression and outcome of vitreoretinal disease including RVO. This inflammation is marked by activated immune cells, such as macrophages, which produce inflammatory molecules and proteolytic enzymes that transform stable plaques into vulnerable, unstable structures (Hansson 2005; Virmani et al. 2006) . Heparanase originates from plaque-residing macrophages and creates a vicious cycle by recruiting and activating more macrophages in an autocrine manner ). The molecular mechanism of cytokine induction by heparanase involves TLRs, a family of type I transmembrane proteins . TLR activation leads to downstream signalling via NF-jB which activates the transcription of proinflammatory mediators such as TNFa, interferon, monocyte chemo-attractant protein-1 (MCP-1), interleukin-1 (IL-1), IL-6 and IL-8 (Kawai & Akira 2010) . Significantly elevated levels of these mediators have been found in both the aqueous and vitreous of patients with RVO, especially CRVO (Funk et al. 2009; Yoshimura et al. 2009 ).
In addition to inflammation, heparanase also accelerates the proliferation of smooth muscle cells (Myler & West 2002) , facilitates matrix metalloproteinase-(MMP) and cathepsinmediated destruction of the extracellular matrix (Baker et al. 2009 ) and functions as a pro-coagulation mediator, enhancing expression of tissue factor and generation of factor Xa (two critical components in blood coagulation) (Nadir et al. 2010) .
Importantly, heparanase also induces vascular endothelial growth factor (VEGF) expression, which is elevated in the aqueous and vitreous of patients with CRVO and BRVO (Noma et al. 2005, 2010; Zetser et al. 2006) . VEGF acts as an angiogenic and vasopermeable factor on endothelial cells (Aiello et al. 1994 ) and is associated with retinal vessel dilatation, breakdown of the blood retinal barrier and retinal new vessel formation, leading to many of the associated neovascular complications of RVO (Ozaki et al. 1997) . The levels of VEGF correlate with both the severity of macular oedema and extent of retinal ischaemia after RVO (Noma et al. 2008 (Noma et al. , 2009 . Our results show a significant increase in heparanase activity and protein levels after adjusting for multiple RVO risk factors, including hypertension, diabetes and hyperlipidemia. Heparanase likely has a synergistic effect on the development of RVO with these risk factors. For example, hyperglycaemia and hyperlipidemia can provoke lysosomal release of endothelial heparanase, its nuclear translocation and activation of genes controlling glucose metabolism and inflammation (Wang et al. 2009 ). This synergy emphasizes the clinical relevance of heparanase in the pathophysiology of RVO and the potential for its use as a predictor of RVO in patients with clinical risk factors (e.g. hypertension, diabetes). Our findings also support the potential role of heparanase-inhibiting compounds, some of which have already entered clinical trials in patients with cancer (e.g. PI-88, SST0001), in treating and/or preventing RVO.
Our study has a number of limitations. First of all, sample size of the three study groups is relatively small, especially for the BRVO group. This may render the conclusion of the study less representative. However, we were able to show a clear statistically significant increase in heparanase protein levels, which was also consistent with heparanase activity. Secondly, we were only able to measure systemic levels of heparanase protein and activity (rather than direct levels in plaques), but this methodology is consistent with other studies in the literature assessing different cardiovascular outcomes (Baker et al. 2009; Vlodavsky et al. 2013 ). In addition, there were significant technical difficulties in obtaining plaque samples from such small vessels as the ocular vasculature.
Our study provides the first direct clinical link between systemic heparanase activity and heparanase protein levels with RVO, suggesting a critical role for heparanase in the pathophysiology of RVO. More research is required to determine the precise biomolecular mechanisms linking heparanase with RVO (and its risk factors) and in developing both diagnostic and treatment options for this debilitating disease.
